Thrombosis |
From the Research Division, Joslin Diabetes Center (H.-C.C., J.L.B., A.C.C., E.P.F.), and Beth Israel Deaconess Medical Center (A.S.P., S.I., J.H.), Harvard Medical School, Boston, Mass.
Correspondence to Edward P. Feener, PhD, Research Division, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215. E-mail Edward.Feener{at}joslin.harvard.edu
AbstractAlthough the renin-angiotensin system has been implicated in increasing plasminogen activator inhibitor-1 (PAI-1) expression, the role of the angiotensin type 1 (AT1) receptor is controversial. This report examines the effects of angiotensin peptides, angiotensin-converting enzyme inhibition, and AT1 antagonism on rat aortic and cardiac PAI-1 gene expression. In vitro, angiotensin (Ang) I, Ang II, and angiotensin Arg2-Phe8 (Ang III) were potent agonists of PAI-1 mRNA expression in rat aortic smooth muscle cells (RASMCs), and stimulation of PAI-1 by these peptides was blocked by the AT1 antagonist candesartan. Angiotensin Val3-Phe8 (Ang IV) and angiotensin Asp1-Pro7 (Ang [1-7]) did not affect PAI-1 expression in RASMCs. In neonatal rat cardiomyocytes, Ang II increased PAI-1 mRNA expression by 4-fold (P<0.01), and this response was completely blocked by AT1 receptor antagonism. Continuous intrajugular infusion of Ang II into Sprague-Dawley rats for 3 hours increased aortic and cardiac PAI-1 mRNA expression by 17- and 9 fold, respectively, and these Ang II responses were completely blocked by coinfusion with candesartan. Aortic and cardiac PAI-1 expressions were compared in spontaneously hypertensive rats and Wistar-Kyoto rats. PAI-1 expression in the aorta and heart from spontaneously hypertensive rats was 5.8-fold and 2-fold higher, respectively, than in control Wistar-Kyoto rats (P<0.05). Candesartan treatment for 1 week reduced aortic and cardiac PAI-1 expression in spontaneously hypertensive rats by 94% and 72%, respectively (P<0.05), but did not affect vascular PAI-1 levels in Wistar-Kyoto rats. These results demonstrate a role for the AT1 receptor in mediating the effects of Ang II on aortic and cardiac PAI-1 gene expression.
Key Words: angiotensin II plasminogen activator inhibitor hypertension aorta vascular smooth muscle cells
This article has been cited by other articles:
![]() |
Y. Xia, S. M. Ramin, and R. E. Kellems Potential Roles of Angiotensin Receptor-Activating Autoantibody in the Pathophysiology of Preeclampsia Hypertension, August 1, 2007; 50(2): 269 - 275. [Full Text] [PDF] |
||||
![]() |
A. D. Weisberg, F. Albornoz, J. P. Griffin, D. L. Crandall, H. Elokdah, A. B. Fogo, D. E. Vaughan, and N. J. Brown Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 Attenuates Angiotensin II/Salt-Induced Aortic Remodeling Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 365 - 371. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Roncal, J Orbe, J.A Rodriguez, M Belzunce, O Beloqui, J Diez, and J.A Paramo Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension Cardiovasc Res, July 1, 2004; 63(1): 176 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-C. Chen and E. P. Feener MEK1,2 response element mediates angiotensin II--stimulated plasminogen activator inhibitor-1 promoter activation Blood, April 1, 2004; 103(7): 2636 - 2644. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Koh, J. Y. Ahn, S. H. Han, D. S. Kim, D. K. Jin, H. S. Kim, M.-S. Shin, T. H. Ahn, I. S. Choi, and E. K. Shin Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients J. Am. Coll. Cardiol., September 3, 2003; 42(5): 905 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sawathiparnich, L. J. Murphey, S. Kumar, D. E. Vaughan, and N. J. Brown Effect of Combined AT1 Receptor and Aldosterone Receptor Antagonism on Plasminogen Activator Inhibitor-1 J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3867 - 3873. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yia, H. Wne, S. Bobst, M.-C. Day, and R. E. Kellems Maternal Autoantibodies From Preeclamptic Patients Active Angiotensin Receptors on Human Trophoblast Cells Reproductive Sciences, February 1, 2003; 10(2): 82 - 93. [Abstract] [PDF] |
||||
![]() |
N. J. Brown, S. Kumar, C. A. Painter, and D. E. Vaughan ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism: Differential Effects on PAI-1 Over Time Hypertension, December 1, 2002; 40(6): 859 - 865. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xia, H. Y. Wen, and R. E. Kellems Angiotensin II Inhibits Human Trophoblast Invasion through AT1 Receptor Activation J. Biol. Chem., June 28, 2002; 277(27): 24601 - 24608. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kobayashi, S. Nakano, S.-i. Mita, T. Kobayashi, T. Honda, Y. Tsubokou, and H. Matsuoka Involvement of Rho-Kinase Pathway for Angiotensin II-Induced Plasminogen Activator Inhibitor-1 Gene Expression and Cardiovascular Remodeling in Hypertensive Rats J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 459 - 466. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Mustafa, Joo Hyung Lee, Siew Yeen Chai, A. L Albiston, S. G McDowall, and F. A. Mendelsohn Bioactive angiotensin peptides: focus on angiotensin IV Journal of Renin-Angiotensin-Aldosterone System, December 1, 2001; 2(4): 205 - 210. [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |